CN110869052A - 癌症的治疗 - Google Patents

癌症的治疗 Download PDF

Info

Publication number
CN110869052A
CN110869052A CN201780078679.8A CN201780078679A CN110869052A CN 110869052 A CN110869052 A CN 110869052A CN 201780078679 A CN201780078679 A CN 201780078679A CN 110869052 A CN110869052 A CN 110869052A
Authority
CN
China
Prior art keywords
herpes simplex
simplex virus
oncolytic herpes
tumor
oncolytic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780078679.8A
Other languages
English (en)
Chinese (zh)
Inventor
J·考纳
T·克里普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vito Bio Pharmaceutical Co ltd
Original Assignee
Vito Bio Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1622214.3A external-priority patent/GB201622214D0/en
Priority claimed from GBGB1702565.1A external-priority patent/GB201702565D0/en
Application filed by Vito Bio Pharmaceutical Co ltd filed Critical Vito Bio Pharmaceutical Co ltd
Publication of CN110869052A publication Critical patent/CN110869052A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nuclear Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780078679.8A 2016-12-23 2017-12-22 癌症的治疗 Pending CN110869052A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1622214.3 2016-12-23
GBGB1622214.3A GB201622214D0 (en) 2016-12-23 2016-12-23 treatment of cancer
GB1702565.1 2017-02-17
GBGB1702565.1A GB201702565D0 (en) 2017-02-17 2017-02-17 Treatment of cancer
PCT/EP2017/084421 WO2018115458A1 (en) 2016-12-23 2017-12-22 Treatment of cancer

Publications (1)

Publication Number Publication Date
CN110869052A true CN110869052A (zh) 2020-03-06

Family

ID=61189397

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780078679.8A Pending CN110869052A (zh) 2016-12-23 2017-12-22 癌症的治疗

Country Status (6)

Country Link
US (1) US20200000861A1 (enExample)
EP (1) EP3558377A1 (enExample)
JP (1) JP2020501589A (enExample)
CN (1) CN110869052A (enExample)
CA (1) CA3047508A1 (enExample)
WO (1) WO2018115458A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170133A1 (en) * 2017-03-15 2018-09-20 Amgen Inc. Use of oncolytic viruses, alone or in combination with a checkpoint inhibitor, for the treatment of cancer
MX2019012741A (es) 2017-04-28 2020-01-21 Merck Sharp & Dohme Biomarcadores para agentes terapeuticos contra el cancer.
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
US20230023987A1 (en) * 2019-12-20 2023-01-26 Board Of Regents, The University Of Texas System Methods for treating cancer comprising low dose radiation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163547A (zh) * 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9102126D0 (en) 1991-01-31 1991-03-13 Smithkline Beecham Biolog Novel vaccine
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6207157B1 (en) 1996-04-23 2001-03-27 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for nontypeable Haemophilus influenzae
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
JP2007511216A (ja) 2003-11-17 2007-05-10 クルセイド ラボラトリーズ リミテッド 変異ウイルス
GB0326798D0 (en) 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP3153526B1 (en) * 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2009148488A2 (en) * 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US20130022629A1 (en) 2010-01-04 2013-01-24 Sharpe Arlene H Modulators of Immunoinhibitory Receptor PD-1, and Methods of Use Thereof
CN103079644B (zh) 2010-06-11 2017-02-15 协和发酵麒麟株式会社 抗tim‑3抗体
US9163087B2 (en) 2010-06-18 2015-10-20 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2013169739A1 (en) * 2012-05-07 2013-11-14 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
US9862932B2 (en) * 2012-07-24 2018-01-09 The General Hospital Corporation Oncolytic virus therapy for resistant tumors
EP2879707A4 (en) * 2012-08-01 2016-05-11 Tetralogic Pharm Corp Combination therapy
GB201408297D0 (en) * 2014-05-12 2014-06-25 Virttu Biolog Ltd Treatment of cancer
EP3217993A1 (en) * 2015-07-20 2017-09-20 Virttu Biologics Limited Treatment of cancer by infusion of oncolytic herpes simplex virus to the blood

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106163547A (zh) * 2014-03-15 2016-11-23 诺华股份有限公司 使用嵌合抗原受体治疗癌症

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KERI A. STREBY等: "Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients", 《CANCER THERAPY: CLINICAL》 *
KEVIN J HARRINGTON等: "Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy", 《EXPERT REVIEW OF ANTICANCER THERAPY》 *
TIMOTHY CRIPE等: "A phase I dose escalation study of intratumoural or intravenous herpes simplex virus-1 mutant HSV1716 in pediatric/young adult patients with refractory non-central nervous system solid tumours", 《HUMAN GENE THERAPY》 *

Also Published As

Publication number Publication date
EP3558377A1 (en) 2019-10-30
WO2018115458A1 (en) 2018-06-28
JP2020501589A (ja) 2020-01-23
US20200000861A1 (en) 2020-01-02
CA3047508A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
US10813958B2 (en) Use of oncolytic herpes simplex virus, alone or in combination with immune check-point inhibitor, in the treatment of cancer
US20200171151A1 (en) Live and in-vivo tumor specific cancer vaccine system developed by co-administration of either at least two or all three of the following components such as tumor cells, an oncolytic virus vector with transgenic expression of gm-csf and an immune checkpoint modulator
EP3365062B1 (en) Methods of treating solid or lymphatic tumors by combination therapy
US12370229B2 (en) Methods of treating bladder cancer
JP2019501671A (ja) 操作された腫瘍溶解性ウイルス
US20200000861A1 (en) Treatment of cancer
KR102950505B1 (ko) M2 결함성 폭스바이러스
TWI817958B (zh) 用於治療肝癌之組合物及方法
US20250032611A1 (en) Gene editing and engineering stem cells for drug delivery
KR20230110737A (ko) Cd19를 표적화하는 유전자 조작된 t 세포를 사용한 b 세포 악성종양의 동종 세포 요법
Wang et al. The potential of swine pseudorabies virus attenuated vaccine for oncolytic therapy against malignant tumors
Speranza et al. Preclinical mouse models for analysis of the therapeutic potential of engineered oncolytic herpes viruses
Guinn et al. 8th international conference on oncolytic virus therapeutics
Frendéus et al. Vector-based Cancer Immunotherapy
RU2802962C2 (ru) Композиции и способы лечения рака печени
Liu et al. Current Status and Evolution of Immunotherapy in Glioma Management
Denton Modulation of tumor associated macrophages enhances oncolytic herpes virotherapy in preclinical models of Ewing sarcoma
Smith Exploiting the Glioblastoma Tumor Microenvironment for Enhanced Oncolytic Herpes Simplex Virus Therapy
HK40022407B (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
HK40022407A (en) Cg0070 for treating bcg resistant bladder carcinoma in situ
HK1255016A1 (en) Methods of treating solid or lymphatic tumors by combination therapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200306